Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves Novartis biosimilar to Amgen’s Enbrel

The U.S. Food and Drug Administration approved Novartis AG’s biosimilar version of Amgen Inc.’s arthritis drug Enbrel.

Read More »

Coherus says USPTO to review AbbVie’s Humira

Coherus BioSciences said the U.S. Patent and Trademark office agreed to review its petition to make a copy of AbbVie’s top-selling arthritis drug Humira.

Read More »

New drugs fuel strong Pfizer results; company raises 2016 forecasts

Pfizer Inc. reported quarterly results that blew past analyst estimates on sales of its new cancer and arthritis treatments and the acquisition last year of the hospital products company Hospira.

Read More »

AstraZeneca sells U.S. gout drug rights to Ironwood for up to $265 million

AstraZeneca Plc said Ironwood Pharmaceuticals Inc. would buy the U.S. marketing rights for its newly approved gout drug for up to $265 million.

Read More »

Cara Therapeutics’ arthritis drug meets main goal in study

Cara Therapeutics Inc said its arthritis drug met the main goal of reducing pain in patients in the first mid-stage study. The oral drug, CR845, was being evaluated in patients with osteoarthritis in the knee or hip, the company said on Wednesday. Osteoarthritis, also known as degenerative arthritis, is a type of disease that results […]

Read More »

FDA panel votes in favor of approving AstraZeneca’s gout drug

An independent panel of advisers to the U.S. Food and Drug Administration on Friday voted 10-4 in favor of approving AstraZeneca Plc’s gout drug. All 10 who backed the drug, lesinurad, qualified their vote by urging the FDA to ask AstraZeneca for studies after the drug’s launch to gauge its long-term effectiveness and safety. Gout […]

Read More »

FDA staff reviewers question safety of AstraZeneca’s gout drug

Staff reviewers of the U.S. Food and Drug Administration have raised questions about the safety of AstraZeneca Plc’s gout treatment. Reviewers pointed to higher death rates, cardiovascular issues and kidney-related side effects in patients who took the drug, lesinurad, a preliminary review published on Wednesday showed. Industry analysts forecast annual sales of the drug to […]

Read More »

Troubled XOMA Nails Immuno-Oncology Pact Worth $530 Million+ With Novartis

BERKELEY, Calif. – Swiss-based Novartis AG (NVS) struck a deal worth more than $500 million with XOMA Corporation (XOMA) to acquire rights to the company’s anti-transforming growth factor-beta (TGFb) antibody program, Xoma announced this morning. Under terms of the deal, Xoma will receive $37 million in upfront payments, with the remaining $480 million in regulatory […]

Read More »

Depression may increase heart risk in rheumatoid arthritis

Mental health problems like anxiety and depression may partly explain why people with rheumatoid arthritis have an increased risk of cardiovascular disease, according to a new study. Researchers linked anger, anxiety, depressive symptoms, job stress and low social support to increasing risk of hardening of the arteries, or atherosclerosis, for people with rheumatoid arthritis (RA). […]

Read More »

Knee replacement may ‘turn back the clock’ for arthritis pain

Knee replacement surgery may significantly ease pain and improve leg function and quality of life in patients with osteoarthritis or rheumatoid arthritis (RA), a recent study suggests. While surgery doesn’t restore the same level of comfort and function patients had in their younger years, before they developed arthritis, the authors write in the journal Arthritis […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom